Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 55

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 55
---
27 Asset Transfer

On January 29, 2025, Kineta entered into the GigaGen Agreement with GigaGen. Effective as of the date thereof, the GigaGen agreement terminated
the existing CD27 Agreement between the two parties, which was dated June 9, 2021, and subsequently amended on July 31, 2022, December 21, 2022 and May 25, 2023. The termination is mutually agreed upon and is not due to any fault or breach by
either party. As part of the termination, GigaGen waived all fees accrued, due, or payable by Kineta, totaling $180,000. Kineta agreed to assign all solely owned and jointly owned right, titles, and interests in certain intellectual property and
patents related to the CD27 program back to GigaGen. Additionally, pursuant to the GigaGen Agreement, Kineta will transfer all related data and regulatory filings to GigaGen by February 8, 2025. Kineta also granted to GigaGen, an exclusive,
perpetual, irrevocable, unrestricted, fully paid-up, royalty-free, worldwide, transferable, sublicensable (through multiple tiers) right and license to use, copy, reproduce, modify, create derivative works, make, have made, distribute, commercialize
and otherwise fully exploit all information in respect of Kineta’s CD27 program to the full extent of Kineta’s rights therein. Both parties released each other from any claims or liabilities arising from the CD27 Agreement, except for
those specified in the GigaGen Agreement.

Recommendation of the TuHURA Board of Directors; TuHURA’s Reasons for the Mergers (see page 223)

The TuHURA Board of Directors unanimously recommends that TuHURA stockholders vote “FOR” the Authorized Share
Increase Proposal, “FOR” the Delaware Conversion Proposal , “FOR” the director nominees named in the Director Election Proposal, “FOR” the Executive Compensation Proposal, “FOR” the
Auditor Ratification Proposal and “FOR” the TuHURA Adjournment Proposal, each as described in further detail in this joint proxy statement/prospectus. For a description of the factors considered by the TuHURA Board of Directors

31

in reaching its decision to approve the Merger Agreement and the transactions contemplated thereby, including the Mergers and the Authorized Share Increase, and additional information on the
recommendation of the TuHURA Board of